GLP-1 Navigator

@AlecStapp It’s less techno-solutionism and more biological validation. GLP-1s worked because they aligned with existing physiology: satiety signaling, energy balance, reward pathways. The breakthrough wasn’t just tech — it was targeting the right system.

GLP-1 drugs are the ultimate validation of the techno-solutionist approach to society's most challenging problems. The obesity crisis seemed liked it would just get worse and worse forever. Scolding from public health officials didn't work. Proposals to completely overhaul our food systems were dead on arrival. Instead, we invented a weekly shot (based on Gila monster venom!) that fixes obesity directly. And now, thanks to the economic incentives in our biomedical industry, we have follow-on drugs that will be cheaper, even more effective, and easier to administer (by taking a pill instead of a shot). Policymakers should be focused on figuring out how we can get more breakthrough drugs like GLP-1s (and faster). They also should think hard about which slopulist ideas might inadvertently kill the goose that lays the golden eggs.

@cremieuxrecueil GLP-1s don’t “cause” muscle loss. Unmanaged weight loss does. The difference is whether you protect lean mass during the deficit.

A new GLP-1RA meta-analysis just came out. It compared lean mass losses in trials using GLP-1RAs to trials where people lost weight by changing their behaviors. GLP-1RAs caused the exact same amount of muscle loss as lifestyle-only weight loss, as expected if it's identical.

@DocPriyamMD Curious how you sequence this in practice: Lifestyle first → then GLP-1 or parallel from the start? Feels like timing may matter as much as the interventions themselves.

Listen, as a doctor, I see patients every day looking for a "magic pill" for insulin resistance. The truth?? Evidence-based medicine shows it’s actually reversible, but it requires a clinical blueprint not just willpower. Here’s how we actually move the needle in 2026: 1️⃣The 10% Tipping Point: Losing just 10% of your body weight is the metabolic "reset" button. It clears ectopic fat from your liver and pancreas, which can drop your HOMA-IR (insulin resistance score) by a staggering 65%!! 2️⃣Muscle is a Glucose Sink: You need to lift. Resistance training triggers GLUT4 translocation.....this lets your muscles suck up glucose without needing a ton of insulin. More muscle = a bigger metabolic sink. 3️⃣The Protein Priority: High-leucine protein (lean meats, legumes) is critical. It protects your muscle mass while you lose fat. Don't fall into the "skinny fat" trap where you lose weight but your metabolism actually slows down. 4️⃣Watch the Saturated Fats: It’s not just about carbs. High saturated fat can actually "clog" the insulin signaling pathway in your cells. Swap the butter for fiber-rich whole foods to keep the pipes clean. 5️⃣The GLP-1 Revolution: If lifestyle isn't enough, GLP-1 and GIP/GLP-1 dual agonists are game-changers. They don't just mask blood sugar; they help reverse the underlying pathology by targeting the brain-gut-pancreas axis. ⚠️ Clinical Disclaimer: While GLP-1 agonists are highly effective, they are serious medications. They must only be used under a doctor’s supervision after a formal prescription and a thorough metabolic workup to monitor for side effects like pancreatitis or gallbladder issues.

@TejasTekk GLP-1s are appetite regulators, not body composition optimizers. How you train and eat determines what weight you lose.

GLP-1 drugs do not replace exercise or protein. That idea is not just wrong. It is potentially harmful. Semaglutide and tirzepatide can help with weight loss. But if you do not lift and do not eat enough protein, a meaningful share of that weight loss can come from lean mass, not just fat. GLP-1 medications are prescription drugs, not casual weight-loss tools. They should be used only if a qualified medical doctor evaluates you and specifically recommends them. Do not self-medicate. Do not take them based on social media advice, peer pressure, or online hype. These drugs need proper indication, dose titration, monitoring, and follow-up.

@MichaelMindrum Curious how you think about: indefinite therapy vs dose tapering in super-responders? Feels like we’re still early in defining long-term management strategies.

My last note from two years ago ended with: **He should NEVER come off a GLP1a as long as there isn't an absolute contra-indication. He is a "super-responder" to GLP1a therapy and will regain weight if he stops.** Received a referral today: patient stopped GLP1 with weight regain and now elevated glucose. Please see for reassessment. I guess I'm still needed.

@DrJesseMorse I wonder if “anti-aging” is just what happens when you aggressively treat metabolic dysfunction early. We may be labeling the downstream effect rather than the mechanism.

I personally think the GLP-1s, especially Retatrutide (low dose) will end up being proven as anti-aging tools. That’s how I am treating them. SGLT2 inhibitors as well.

People call it “weight regain” after stopping GLP-1s.But it’s really:Reversion to a biologically defended set point once therapy is removed.We don’t expect chronic diseases to stay controlled off treatment.Obesity may need to be managed the same way.

If someone loses 20% body weight on a GLP-1 and regains after stopping… Was the drug ineffective — or was the disease chronic? We don’t ask this in other conditions... Learn more here: #GLP1" target="_blank" rel="nofollow noopener">implicit.cloud/expert#GLP1

@DrNadolsky The real question isn’t “Do people regain?” It’s: How do we design sustainable maintenance — dose tapering, combination therapy, resistance training, behavioral scaffolding? That’s the next frontier.

You usually regain weight after stopping a GLP-1 medicine. You usually regain weight after you stop your diet and exercise program. You usually have an increase in your blood pressure when you stop your blood pressure medicine.

@maxmarchione If 15–17% used to feel revolutionary, and 28% is now possible… The real question is durability. What do 3–5 year maintenance curves look like for triple agonists?

The evolution of GLP-1s: GLP-1 agonist (semaglutide) = targets one receptor. ~15-17% weight loss. Dual agonist (tirzepatide) = GLP-1 + GIP. ~20-22% weight loss. Triple agonist (retatrutide) = GLP-1 + GIP + glucagon. Up to 28.7% weight loss. Retatrutide might very well be the best-selling drug of all time

GLP-1s aren’t “killing” bariatric surgery. They’re reshaping the treatment ladder. Surgery likely becomes: • Later-line • Higher BMI • More complex metabolic cases • Or combined with GLP-1 maintenance This isn’t replacement. It’s re-segmentation of obesity care.

@cremieuxrecueil This may be less “replacement” and more “re-segmentation.” GLP-1s absorb moderate obesity + early metabolic disease. Surgery becomes: • Extreme BMI • Complication-driven • Or combination therapy Therapeutic ladder is changing.

GLP-1s are affecting bariatric surgeons. The public views GLP-1s as an alternative to bariatric surgery, and as a result, bariatric surgeons are having to take up other types of surgery. In about two years, the bariatric surgery share of their case mix has almost halved!

GLP-1 information is fragmented. Trial data in one place. Mechanism papers in another. Dosing nuance scattered across threads. So I built a GLP-1 AI Navigator on Implicit. You can interrogate it like a research partner. Explore it here: #GLP1" target="_blank" rel="nofollow noopener">implicit.cloud/expert#GLP1 #GLP1

@Ashwinreads Curious whether this is: A) appetite suppression → caffeine substitution B) more gym engagement C) GI tolerability pushing toward liquids Or some combination of all three.

as someone who drinks a copious amount of zero sugar monster energy drinks before and after the gym- mainly for the caffeine hit and not wanting sugary surplus of calories - i’m not surprised glp-1 users are boosting energy drink sales.

6/6 What do you think? Should we treat GLP‑1 drugs as kidney‑friendly meds based on the current evidence, or wait for firmer proof? Share your take or any personal experience with these agents. #KidneyHealth

5/6 A popular mechanistic claim is that GLP‑1 directly blocks the tubular Na⁺/H⁺ exchanger NHE‑3. That’s solid in rodent labs, but human studies have never demonstrated a direct NHE‑3 inhibition. The human kidney’s response seems to come from the systemic hormonal shifts.

1/6 Why are GLP‑1 receptor agonists—once only a blood‑sugar fix—now being hailed as kidney protectors? The buzz hides a nuanced story that most people don’t see. #diabetes